Nektar Therapeutics (Nasdaq: NKTR) announced the publication of Phase 2b trial results for its drug candidate rezpegaldesleukin in The Lancet ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE